Exclusive Summary

• Pioneering mRNA Asset: The first therapeutic mRNA vaccine approval for clinical trials targeting Cervical Intraepithelial Neoplasia (CIN) in China, demonstrating leading technological status.
• Addressing Critical Unmet Need: Offers a non-invasive therapeutic alternative to surgical procedures (LEEP/conization), preserving fertility and reducing reproductive risks for women.
• Validated Regulatory Status: Successfully obtained IND approval from the Chinese NMPA in July 2024 as a Class 1 New Drug, de-risking the initial regulatory pathway.

Asset Materials

Contact Us for Full Materials